Good Shingles Vaccine Sales Prompts GSK To Raise Profit Forecast

The sale of shingles vaccine of GlaxoSmithKline beat market expectations and the continued good performance of the company’s older medicines, including HIV treatments prompted the drug making company to raise its annual profit forecast for the second time this year. Following the announcement by the British drug maker about its expectations of profit for the…

Japanese Car Makers Buck Downturn In Chinese Auto Market

The first eight months of the current year have been good for Japanese car companies operating in China despite the prolonged downturn in the Chinese auto market, with 14 straight months of contraction, as well as the broader Chinese economy. According to the China Association of Automobile Manufacturers, in August, the overall vehicle sale in…

Subsidiary For Autonomous Driving Set Up By Volkswagen

The pressure for making rapid technological advancement in the field of autonomous driving and self driving cars is pushing global auto companies to invest more time resources. This is evident in the decision of the German car manufacturer Volkswagen AG to create a new subsidiary called Volkswagen Autonomy (VWAT)completely dedicated to self driving tech. The…

Surge In Sales Of Cancer Drug And Heart Medicine Prompts Pfizer To Raise 2019 Forecast

An increase in the sale of cancer drug Ibrance as well as a great launch for its new heart medicine Vyndaqel propelled the third quarter profits for Pfizer Inc which beats estimates of analysts after the company announced its earnings on Tuesday. The strong third quarter performance prompted the company, the largest drugmaker of the…

Weak Advertisement And Low Demand Hit Twitter Revenue, Misses Expectations

Twitter Inc cited issues with advertising efforts, which included product bugs and unusually low demand over the summer as the reasons for the social media company posting both revenues and profits much lower than what the market was expecting for the third quarter. The bad earnings report also resulted in a sharp drop in Twitter…

Biogen Seeks FDA Approval For Its Once-Doomed Drug For Alzheimer’s

There is reasonable confidence with Biogen CEO Michel Vounatsos about getting the approval for the drugmaker’s experimental Alzheimer’s drug from the United States Food and Drug Administration. “We worked in full transparency with the regulator,” Vounatsos said in a television interview while also emphasizing that all of the data about the drug that the company…